Form 4: Day One Biopharmaceuticals Officer Lauren Merendino Reports Stock Transactions

Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.

Summary

• Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions on May 15 and 16, 2025.
• Merendino acquired shares through the vesting of Restricted Stock Units (RSUs) and disposed of shares to cover tax liabilities.
• On May 15, 2025, 3,162, 3,687 and 3,687 shares were acquired through RSU vesting.
• On May 16, 2025, 3,927 shares were sold at a weighted average price of $6.2579 per share.
• The sales were part of block trades with prices ranging from $6.19 to $6.32.
• Following the reported transactions, Merendino beneficially owns 35,161 shares of common stock and varying amounts of RSUs.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock transactions. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company officers and directors. This filing indicates standard compensation practices involving stock and RSUs.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biopharmaceutical industry to align the interests of executives with those of shareholders.
• RSUs vesting over time with quarterly installments is a typical vesting schedule.
• Selling shares to cover tax liabilities associated with RSU vesting is a standard practice among executives receiving equity compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, DAWN, Day One Biopharmaceuticals, Merendino, Lauren Merendino